RESUMEN
[structure] selective estrogen receptor modulator (SERM), Lasofoxifene (CP-336156), was prepared by an enzyme-catalyzed asymmetric deacylation with high optical purity and excellent yield even though the hydrolytic site is remote from the chiral centers.
Asunto(s)
Pirrolidinas/síntesis química , Moduladores Selectivos de los Receptores de Estrógeno/síntesis química , Tetrahidronaftalenos/síntesis química , Catálisis , Remoción de Radical Alquila , Hidrólisis , Estereoisomerismo , Difracción de Rayos XRESUMEN
Saccharopepsin is a vacuolar aspartic proteinase involved in activation of a number of hydrolases. The enzyme has great structural homology to mammalian aspartic proteinases including human renin and we have used it as a model system to study the binding of renin inhibitors by X-ray crystallography. Five medium-to-high resolution structures of saccharopepsin complexed with transition-state analogue renin inhibitors were determined. The structure of a cyclic peptide inhibitor (PD-129,541) complexed with the proteinase was solved to 2.5 A resolution. This inhibitor has low affinity for human renin yet binds very tightly to the yeast proteinase (K(i)=4 nM). The high affinity of this inhibitor can be attributed to its bulky cyclic moiety spanning P(2)-P(3)' and other residues that appear to optimally fit the binding sub-sites of the enzyme. Superposition of the saccharopepsin structure on that of renin showed that a movement of the loop 286-301 relative to renin facilitates tighter binding of this inhibitor to saccharopepsin. Our 2.8 A resolution structure of the complex with CP-108,420 shows that its benzimidazole P(3 )replacement retains one of the standard hydrogen bonds that normally involve the inhibitor's main-chain. This suggests a non-peptide lead in overcoming the problem of susceptible peptide bonds in the design of aspartic proteinase inhibitors. CP-72,647 which possesses a basic histidine residue at P(2), has a high affinity for renin (K(i)=5 nM) but proves to be a poor inhibitor for saccharopepsin (K(i)=3.7 microM). This may stem from the fact that the histidine residue would not bind favourably with the predominantly hydrophobic S(2) sub-site of saccharopepsin.
Asunto(s)
Ácido Aspártico Endopeptidasas/metabolismo , Oligopéptidos/química , Oligopéptidos/metabolismo , Inhibidores de Proteasas/química , Inhibidores de Proteasas/metabolismo , Renina/antagonistas & inhibidores , Ácido Aspártico Endopeptidasas/antagonistas & inhibidores , Ácido Aspártico Endopeptidasas/química , Sitios de Unión , Cristalografía por Rayos X , Humanos , Enlace de Hidrógeno , Cinética , Modelos Moleculares , Oligopéptidos/farmacología , Inhibidores de Proteasas/farmacología , Estructura Secundaria de Proteína , Saccharomyces cerevisiae/química , Proteínas de Saccharomyces cerevisiae , Electricidad Estática , Especificidad por Sustrato , TermodinámicaAsunto(s)
Antagonistas de Estrógenos/farmacología , Pirrolidinas/farmacología , Receptores de Estrógenos/agonistas , Receptores de Estrógenos/antagonistas & inhibidores , Tetrahidronaftalenos/farmacología , Administración Oral , Animales , Disponibilidad Biológica , Densidad Ósea/efectos de los fármacos , Neoplasias de la Mama/patología , División Celular/efectos de los fármacos , Colesterol/sangre , Antagonistas de Estrógenos/administración & dosificación , Antagonistas de Estrógenos/metabolismo , Antagonistas de Estrógenos/farmacocinética , Etinilestradiol/metabolismo , Femenino , Humanos , Hipolipemiantes/metabolismo , Hipolipemiantes/farmacología , Neoplasias Hormono-Dependientes/patología , Tamaño de los Órganos/efectos de los fármacos , Ovariectomía , Pirrolidinas/administración & dosificación , Pirrolidinas/metabolismo , Pirrolidinas/farmacocinética , Ratas , Tetrahidronaftalenos/administración & dosificación , Tetrahidronaftalenos/metabolismo , Tetrahidronaftalenos/farmacocinética , Células Tumorales Cultivadas , Útero/efectos de los fármacosRESUMEN
We have discovered a new, nonsteroidal, potent estrogen agonist/antagonist, CP-336,156. CP-336,156 binds selectively and with high affinity to the human estrogen receptor-alpha with a half-inhibition concentration of 1.5 nM, which is similar to that seen with estradiol (4.8 nM). When given orally to immature (3-week-old) female Sprague-Dawley rats for 3 days at doses of 0.1, 1.0, 10, or 100 microg/kg x day, unlike 17alpha-ethynyl estradiol, CP-336,156 had no effect on uterine wet or dry weight. Similarly, no uterine hypertrophy was observed in aged (17-month-old) female rats treated (p.o.) with CP-336,156 at 10 or 100 microg/kg x day for 28 days. We also found that CP-336,156 decreased total serum cholesterol and fat body mass and had no effect on lean body mass in these aged female rats. In 5-month-old ovariectomized (OVX) Sprague-Dawley female rats, CP-336,156 completely prevented OVX-induced increases in body weight gain, total serum cholesterol, and serum osteocalcin at doses between 10 and 1000 microg/kg x day after 4 weeks. At these doses, CP-336,156 completely prevented OVX-induced bone loss and inhibited the increased bone turnover associated with estrogen deficiency in lumbar vertebrae, proximal tibiae, and distal femora. Similar to estrogen, CP-336,156 induced apoptosis and p53 expression with a concomitant decrease in the number of tartrate-resistant acid phosphatase-positive multinuclear cells in rat bone marrow cell cultures in vitro, suggesting that the induction of apoptosis may be a mechanism for the estrogenic activities of CP-336,156 in bone. In summary, CP-336,156 is a new, orally active, nonsteroidal, potent estrogen agonist/antagonist that has similar effects in bone as estradiol but without the uterine-stimulating effects associated with estradiol in rats.
Asunto(s)
Composición Corporal/efectos de los fármacos , Huesos/efectos de los fármacos , Colesterol/sangre , Antagonistas de Estrógenos/farmacología , Pirrolidinas/farmacología , Tetrahidronaftalenos/farmacología , Útero/efectos de los fármacos , Tejido Adiposo , Envejecimiento , Animales , Apoptosis , Células de la Médula Ósea/efectos de los fármacos , Células Cultivadas , Femenino , Expresión Génica/efectos de los fármacos , Genes p53 , Tamaño de los Órganos/efectos de los fármacos , Osteocalcina/sangre , Ovariectomía , Ratas , Ratas Sprague-Dawley , Receptores de Estrógenos/metabolismo , Útero/anatomía & histología , Aumento de Peso/efectos de los fármacosRESUMEN
Knowledge of the sequence of a bioactive protein (angiotensinogen) and the availability of a natural product inhibitor lead (pepstatin) were the starting point for discovery of potent penta- and hexapeptide renin inhibitors. Study of the metabolism and disposition of these substances forced the discovery of simpler inhibitors leading to the discovery of oral activity in Terlakiren (22). Modification of physical properties led to the synthesis of aminopiperidine 30, which was identified by oral efficacy profiling. Structural modification to give enzymatic stability produced the bioavailable benzylsuccinate inhibitor 34. Its bioactive monomethylamine metabolite (35, CP-108,671) was subsequently found to have uniformly high oral bioavailability and activity in various species including primates.
Asunto(s)
Oligopéptidos/farmacología , Oligopéptidos/farmacocinética , Inhibidores de Proteasas/farmacología , Inhibidores de Proteasas/farmacocinética , Renina/antagonistas & inhibidores , Renina/química , Administración Oral , Secuencia de Aminoácidos , Aminocaproatos/administración & dosificación , Aminocaproatos/farmacocinética , Aminocaproatos/farmacología , Animales , Sitios de Unión , Disponibilidad Biológica , Presión Sanguínea/efectos de los fármacos , Quimotripsina/antagonistas & inhibidores , Cobayas , Humanos , Cinética , Datos de Secuencia Molecular , Oligopéptidos/administración & dosificación , Inhibidores de Proteasas/administración & dosificación , Conformación Proteica , Renina/sangre , Solubilidad , Relación Estructura-ActividadRESUMEN
We report the X-ray analysis at 2.0 A resolution for crystals of the aspartic proteinase endothiapepsin (EC 3.4.23.6) complexed with a potent difluorostatone-containing tripeptide renin inhibitor (CP-81,282). The scissile bond surrogate, an electrophilic ketone, is hydrated in the complex. The pro-(R) (statine-like) hydroxyl of the tetrahedral carbonyl hydrate is hydrogen-bonded to both active-site aspartates 32 and 215 in the position occupied by a water in the native enzyme. The second hydroxyl oxygen of the hydrate is hydrogen-bonded only to the outer oxygen of Asp 32. These experimental data provide a basis for a model of the tetrahedral intermediate in aspartic proteinase-mediated cleavage of the amide bond. This indicates a mechanism in which Asp 32 is the proton donor and Asp 215 carboxylate polarizes a bound water for nucleophilic attack. The mechanism involves a carboxylate (Asp 32) that is stabilized by extensive hydrogen bonding, rather than an oxyanion derivative of the peptide as in serine proteinase catalysis.
Asunto(s)
Ácido Aspártico Endopeptidasas/química , Secuencia de Aminoácidos , Ácido Aspártico , Ácido Aspártico Endopeptidasas/metabolismo , Sitios de Unión , Enlace de Hidrógeno , Modelos Moleculares , Oligopéptidos/metabolismo , Conformación Proteica , Renina/antagonistas & inhibidores , Difracción de Rayos X/métodosAsunto(s)
Ácido Aspártico Endopeptidasas/química , Renina/antagonistas & inhibidores , Ácido Aspártico Endopeptidasas/antagonistas & inhibidores , Sitios de Unión , Humanos , Técnicas In Vitro , Modelos Moleculares , Estructura Molecular , Oligopéptidos/química , Conformación Proteica , Difracción de Rayos XRESUMEN
The photo "Wolff" rearrangement of readily available 2-diazoceph-3-em oxides (1) directly affords carbapen-2-ems, allowing a facile entry into a ring system previously accessible only by total synthesis, lengthly semisynthesis or fermentation. The chirality of the cephalosporin is accurately translated into the corresponding carbapenem. The resulting 1-oxocarbapenems (2) were selectively transformed through reduction into 1-oxygenated carbapenems and carbapenams (3 and 4, respectively). On microbiological screening, a carbapenem (3c) was found to possess a broad spectrum of activity. An interesting antibacterial profile was discovered for a carbapenam (26).